 Martin McCarter
Concepts (754)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 44 | 2023 | 620 | 6.770 |
Why?
| | Esophageal Neoplasms | 25 | 2023 | 273 | 5.240 |
Why?
| | Skin Neoplasms | 29 | 2023 | 756 | 3.650 |
Why?
| | Esophagectomy | 18 | 2023 | 111 | 3.280 |
Why?
| | Adenocarcinoma | 23 | 2023 | 795 | 2.980 |
Why?
| | Sentinel Lymph Node Biopsy | 21 | 2022 | 99 | 2.460 |
Why?
| | Myeloid-Derived Suppressor Cells | 4 | 2023 | 56 | 2.430 |
Why?
| | Gastrointestinal Stromal Tumors | 10 | 2022 | 43 | 2.310 |
Why?
| | Neoadjuvant Therapy | 12 | 2023 | 304 | 1.810 |
Why?
| | Sentinel Lymph Node | 9 | 2022 | 37 | 1.780 |
Why?
| | Dendritic Cells | 13 | 2019 | 435 | 1.760 |
Why?
| | T-Lymphocytes, Regulatory | 11 | 2022 | 339 | 1.740 |
Why?
| | Pancreatic Neoplasms | 14 | 2021 | 731 | 1.730 |
Why?
| | Neoplasm Recurrence, Local | 18 | 2019 | 858 | 1.630 |
Why?
| | Tumor Escape | 4 | 2017 | 35 | 1.280 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 1355 | 1.260 |
Why?
| | Lymphatic Metastasis | 18 | 2023 | 275 | 1.240 |
Why?
| | Hyperthermia, Induced | 4 | 2020 | 65 | 1.230 |
Why?
| | Neoplasm Staging | 29 | 2023 | 1167 | 1.180 |
Why?
| | Middle Aged | 90 | 2022 | 26737 | 1.100 |
Why?
| | Humans | 186 | 2024 | 114689 | 1.090 |
Why?
| | Hyperglycemia | 3 | 2020 | 292 | 1.090 |
Why?
| | Aged | 76 | 2021 | 19074 | 1.080 |
Why?
| | HIV-1 | 16 | 2022 | 768 | 1.050 |
Why?
| | Retrospective Studies | 49 | 2023 | 12551 | 1.040 |
Why?
| | Neoplasms | 10 | 2024 | 2097 | 1.020 |
Why?
| | Lymph Nodes | 14 | 2023 | 419 | 1.020 |
Why?
| | HIV Infections | 20 | 2022 | 2469 | 1.010 |
Why?
| | CD4-Positive T-Lymphocytes | 13 | 2021 | 959 | 0.990 |
Why?
| | Postoperative Complications | 19 | 2023 | 2128 | 0.990 |
Why?
| | Rectal Neoplasms | 7 | 2023 | 121 | 0.970 |
Why?
| | Intestinal Mucosa | 10 | 2021 | 532 | 0.920 |
Why?
| | Peritoneal Neoplasms | 3 | 2020 | 54 | 0.880 |
Why?
| | Laparoscopy | 7 | 2023 | 398 | 0.830 |
Why?
| | Male | 101 | 2022 | 55599 | 0.830 |
Why?
| | Lymph Node Excision | 8 | 2022 | 139 | 0.820 |
Why?
| | Pancreaticoduodenectomy | 7 | 2021 | 133 | 0.820 |
Why?
| | Cytoreduction Surgical Procedures | 4 | 2020 | 38 | 0.810 |
Why?
| | Female | 110 | 2022 | 59511 | 0.810 |
Why?
| | Tretinoin | 3 | 2023 | 122 | 0.800 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 92 | 0.780 |
Why?
| | Lymphocyte Activation | 11 | 2018 | 1037 | 0.770 |
Why?
| | Sarcoma | 5 | 2022 | 137 | 0.770 |
Why?
| | Stomach Neoplasms | 2 | 2019 | 65 | 0.760 |
Why?
| | Radiosurgery | 4 | 2020 | 299 | 0.740 |
Why?
| | T-Lymphocytes | 6 | 2018 | 1737 | 0.730 |
Why?
| | Pelvic Exenteration | 4 | 2019 | 11 | 0.730 |
Why?
| | Proto-Oncogene Proteins c-kit | 5 | 2022 | 63 | 0.730 |
Why?
| | Survival Analysis | 16 | 2022 | 1211 | 0.690 |
Why?
| | Adult | 60 | 2020 | 30550 | 0.690 |
Why?
| | Prognosis | 22 | 2022 | 3329 | 0.680 |
Why?
| | Splenectomy | 1 | 2020 | 52 | 0.680 |
Why?
| | Gastrointestinal Microbiome | 8 | 2021 | 501 | 0.670 |
Why?
| | Piperazines | 5 | 2014 | 309 | 0.660 |
Why?
| | Pancreatic Cyst | 2 | 2017 | 47 | 0.660 |
Why?
| | Ipilimumab | 2 | 2019 | 27 | 0.660 |
Why?
| | Spleen | 6 | 2017 | 487 | 0.650 |
Why?
| | Anastomotic Leak | 3 | 2023 | 27 | 0.650 |
Why?
| | Myeloid Cells | 3 | 2020 | 126 | 0.640 |
Why?
| | Pyrimidines | 5 | 2014 | 376 | 0.630 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2018 | 124 | 0.620 |
Why?
| | Granulocytes | 2 | 2017 | 77 | 0.620 |
Why?
| | Colorectal Neoplasms | 5 | 2017 | 615 | 0.610 |
Why?
| | Aged, 80 and over | 27 | 2020 | 6347 | 0.600 |
Why?
| | Leukocytes, Mononuclear | 5 | 2021 | 493 | 0.600 |
Why?
| | Monocytes | 2 | 2020 | 504 | 0.590 |
Why?
| | Appendiceal Neoplasms | 1 | 2017 | 14 | 0.590 |
Why?
| | Survival Rate | 17 | 2021 | 1644 | 0.580 |
Why?
| | Gastric Outlet Obstruction | 1 | 2017 | 7 | 0.560 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2023 | 687 | 0.560 |
Why?
| | Pylorus | 1 | 2017 | 13 | 0.550 |
Why?
| | Head and Neck Neoplasms | 5 | 2019 | 427 | 0.550 |
Why?
| | Soft Tissue Neoplasms | 3 | 2022 | 90 | 0.540 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 152 | 0.540 |
Why?
| | Neuromuscular Agents | 1 | 2017 | 30 | 0.530 |
Why?
| | Botulinum Toxins, Type A | 1 | 2017 | 40 | 0.530 |
Why?
| | Leucovorin | 2 | 2019 | 43 | 0.520 |
Why?
| | Antineoplastic Agents | 8 | 2021 | 1879 | 0.500 |
Why?
| | Combined Modality Therapy | 13 | 2023 | 1121 | 0.480 |
Why?
| | Chemoradiotherapy | 5 | 2023 | 188 | 0.470 |
Why?
| | Vitamin B Complex | 1 | 2014 | 38 | 0.470 |
Why?
| | Immune Tolerance | 4 | 2016 | 323 | 0.460 |
Why?
| | Treatment Outcome | 24 | 2023 | 9088 | 0.460 |
Why?
| | Salvage Therapy | 2 | 2014 | 127 | 0.460 |
Why?
| | Lymphocytes | 3 | 2021 | 330 | 0.460 |
Why?
| | Minimally Invasive Surgical Procedures | 6 | 2023 | 154 | 0.450 |
Why?
| | Pelvis | 1 | 2014 | 90 | 0.440 |
Why?
| | Melanoma, Experimental | 3 | 2022 | 89 | 0.440 |
Why?
| | Pancreatectomy | 4 | 2021 | 171 | 0.430 |
Why?
| | Ear, External | 1 | 2013 | 23 | 0.430 |
Why?
| | Ischemic Preconditioning | 2 | 2023 | 28 | 0.430 |
Why?
| | Mohs Surgery | 1 | 2013 | 24 | 0.430 |
Why?
| | Mutation | 8 | 2022 | 3346 | 0.420 |
Why?
| | Follow-Up Studies | 15 | 2019 | 4411 | 0.420 |
Why?
| | Palliative Care | 1 | 2019 | 644 | 0.420 |
Why?
| | Liver Neoplasms | 5 | 2016 | 506 | 0.410 |
Why?
| | T-Lymphocytes, Helper-Inducer | 4 | 2017 | 127 | 0.410 |
Why?
| | Biopsy | 3 | 2023 | 1036 | 0.410 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2014 | 577 | 0.400 |
Why?
| | Esophagogastric Junction | 3 | 2021 | 42 | 0.390 |
Why?
| | Hematologic Diseases | 1 | 2012 | 55 | 0.390 |
Why?
| | Surgical Wound Infection | 1 | 2014 | 248 | 0.390 |
Why?
| | Cytokines | 8 | 2021 | 1841 | 0.390 |
Why?
| | Suppressor Factors, Immunologic | 1 | 2011 | 4 | 0.390 |
Why?
| | Receptors, CCR5 | 3 | 2021 | 54 | 0.380 |
Why?
| | Colonic Neoplasms | 6 | 2012 | 215 | 0.380 |
Why?
| | Prospective Studies | 19 | 2023 | 6220 | 0.380 |
Why?
| | Up-Regulation | 4 | 2012 | 808 | 0.370 |
Why?
| | Induction Chemotherapy | 2 | 2021 | 56 | 0.370 |
Why?
| | Granzymes | 2 | 2021 | 40 | 0.350 |
Why?
| | Conversion to Open Surgery | 2 | 2020 | 14 | 0.350 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2022 | 102 | 0.350 |
Why?
| | Homosexuality, Male | 3 | 2021 | 170 | 0.350 |
Why?
| | Benzamides | 5 | 2014 | 169 | 0.340 |
Why?
| | Esophageal Achalasia | 2 | 2021 | 25 | 0.340 |
Why?
| | Young Adult | 18 | 2019 | 10470 | 0.340 |
Why?
| | Retroperitoneal Neoplasms | 3 | 2021 | 22 | 0.330 |
Why?
| | Medical Oncology | 4 | 2022 | 229 | 0.330 |
Why?
| | Interferon-gamma | 6 | 2019 | 719 | 0.330 |
Why?
| | Mucous Membrane | 4 | 2023 | 108 | 0.330 |
Why?
| | Wounds and Injuries | 4 | 2009 | 749 | 0.320 |
Why?
| | Membrane Glycoproteins | 3 | 2015 | 430 | 0.320 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 2 | 2019 | 10 | 0.320 |
Why?
| | Cell Differentiation | 5 | 2016 | 1701 | 0.320 |
Why?
| | Barrett Esophagus | 3 | 2020 | 147 | 0.320 |
Why?
| | Butyrates | 2 | 2021 | 53 | 0.320 |
Why?
| | Killer Cells, Natural | 2 | 2023 | 380 | 0.310 |
Why?
| | Interleukin-15 | 2 | 2021 | 74 | 0.310 |
Why?
| | Immunity, Mucosal | 3 | 2016 | 84 | 0.310 |
Why?
| | Blood Preservation | 2 | 2009 | 263 | 0.310 |
Why?
| | Chemotherapy, Adjuvant | 9 | 2023 | 332 | 0.310 |
Why?
| | Disease-Free Survival | 8 | 2019 | 620 | 0.290 |
Why?
| | Inflammation Mediators | 2 | 2018 | 477 | 0.290 |
Why?
| | Colon | 3 | 2021 | 233 | 0.290 |
Why?
| | Prostatic Neoplasms | 1 | 2014 | 921 | 0.290 |
Why?
| | Nomograms | 2 | 2019 | 41 | 0.290 |
Why?
| | Dysbiosis | 3 | 2021 | 146 | 0.280 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 12 | 0.280 |
Why?
| | Immunocompromised Host | 1 | 2008 | 195 | 0.270 |
Why?
| | Cells, Cultured | 9 | 2021 | 3886 | 0.270 |
Why?
| | Erythrocyte Transfusion | 1 | 2008 | 189 | 0.270 |
Why?
| | Population Surveillance | 2 | 2021 | 392 | 0.270 |
Why?
| | Splenic Neoplasms | 1 | 2006 | 2 | 0.270 |
Why?
| | Forkhead Transcription Factors | 1 | 2007 | 170 | 0.270 |
Why?
| | Lymphangioma | 1 | 2006 | 7 | 0.260 |
Why?
| | Th2 Cells | 2 | 2005 | 154 | 0.260 |
Why?
| | Pelvic Neoplasms | 3 | 2012 | 18 | 0.260 |
Why?
| | General Surgery | 1 | 2007 | 127 | 0.260 |
Why?
| | Receptors, Cell Surface | 2 | 2021 | 355 | 0.260 |
Why?
| | Immunity, Innate | 4 | 2021 | 720 | 0.260 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2021 | 211 | 0.260 |
Why?
| | Mentors | 1 | 2007 | 156 | 0.260 |
Why?
| | Catheter Ablation | 4 | 2016 | 288 | 0.260 |
Why?
| | Neuroendocrine Tumors | 2 | 2017 | 85 | 0.260 |
Why?
| | Transplantation Immunology | 1 | 2005 | 30 | 0.260 |
Why?
| | Macrophages, Peritoneal | 3 | 2005 | 93 | 0.250 |
Why?
| | Exome | 2 | 2017 | 200 | 0.250 |
Why?
| | Nevus, Epithelioid and Spindle Cell | 1 | 2005 | 8 | 0.250 |
Why?
| | B-Lymphocytes | 3 | 2017 | 766 | 0.250 |
Why?
| | Virus Replication | 5 | 2017 | 395 | 0.250 |
Why?
| | Microbiota | 3 | 2024 | 647 | 0.250 |
Why?
| | Interleukin-10 | 3 | 2016 | 299 | 0.240 |
Why?
| | Radiation Injuries | 2 | 2021 | 128 | 0.240 |
Why?
| | Signal Transduction | 9 | 2023 | 4513 | 0.240 |
Why?
| | Adolescent | 15 | 2019 | 17848 | 0.240 |
Why?
| | Culture Media, Conditioned | 4 | 2011 | 105 | 0.240 |
Why?
| | Nevus, Pigmented | 1 | 2005 | 34 | 0.230 |
Why?
| | Th1 Cells | 2 | 2019 | 123 | 0.230 |
Why?
| | Macrophage Activation | 1 | 2005 | 164 | 0.230 |
Why?
| | Erythrocytes | 1 | 2009 | 591 | 0.230 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 111 | 0.230 |
Why?
| | Feces | 4 | 2021 | 373 | 0.230 |
Why?
| | Anus Neoplasms | 2 | 2003 | 24 | 0.230 |
Why?
| | Lymphangiogenesis | 1 | 2004 | 24 | 0.230 |
Why?
| | Lymphocyte Count | 5 | 2017 | 133 | 0.220 |
Why?
| | Flow Cytometry | 6 | 2017 | 1083 | 0.220 |
Why?
| | Interferon-alpha | 3 | 2015 | 186 | 0.220 |
Why?
| | Education, Medical, Graduate | 1 | 2007 | 368 | 0.220 |
Why?
| | Ruminococcus | 2 | 2021 | 9 | 0.220 |
Why?
| | Enterobacteriaceae | 2 | 2017 | 32 | 0.220 |
Why?
| | In Vitro Techniques | 5 | 2019 | 1016 | 0.220 |
Why?
| | Paget Disease, Extramammary | 1 | 2003 | 3 | 0.220 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2022 | 194 | 0.210 |
Why?
| | Lymphoid Tissue | 3 | 2008 | 62 | 0.210 |
Why?
| | Neoplasm Metastasis | 2 | 2007 | 523 | 0.210 |
Why?
| | Tomography, X-Ray Computed | 6 | 2016 | 2286 | 0.210 |
Why?
| | Lymphoscintigraphy | 2 | 2019 | 9 | 0.210 |
Why?
| | Lysophospholipids | 1 | 2023 | 65 | 0.210 |
Why?
| | Transforming Growth Factor beta | 4 | 2015 | 448 | 0.210 |
Why?
| | Specialties, Surgical | 1 | 2023 | 70 | 0.210 |
Why?
| | Biomarkers, Tumor | 4 | 2017 | 1040 | 0.210 |
Why?
| | Intestines | 2 | 2017 | 326 | 0.210 |
Why?
| | Protein-Energy Malnutrition | 2 | 2003 | 6 | 0.200 |
Why?
| | Salmonella typhimurium | 2 | 2021 | 164 | 0.200 |
Why?
| | Time Factors | 9 | 2014 | 6116 | 0.200 |
Why?
| | Mice | 20 | 2022 | 14869 | 0.200 |
Why?
| | Bacteria | 3 | 2018 | 725 | 0.200 |
Why?
| | Hepatectomy | 2 | 2016 | 119 | 0.200 |
Why?
| | Cell Count | 2 | 2017 | 303 | 0.200 |
Why?
| | Tumor Microenvironment | 5 | 2024 | 430 | 0.200 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 137 | 0.200 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 15 | 0.200 |
Why?
| | Disease Progression | 2 | 2022 | 2380 | 0.200 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 21 | 0.200 |
Why?
| | Imatinib Mesylate | 5 | 2014 | 63 | 0.200 |
Why?
| | HIV Seropositivity | 1 | 2022 | 109 | 0.200 |
Why?
| | Cryosurgery | 2 | 2019 | 52 | 0.200 |
Why?
| | Esophagoscopy | 2 | 2020 | 184 | 0.190 |
Why?
| | Critical Pathways | 1 | 2022 | 75 | 0.190 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 34 | 0.190 |
Why?
| | Acinetobacter | 1 | 2021 | 13 | 0.190 |
Why?
| | Glucose | 3 | 2020 | 897 | 0.190 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2022 | 154 | 0.190 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 139 | 0.190 |
Why?
| | Seminoma | 1 | 2021 | 17 | 0.190 |
Why?
| | ADAM10 Protein | 1 | 2021 | 28 | 0.180 |
Why?
| | Firmicutes | 1 | 2021 | 17 | 0.180 |
Why?
| | Anastomosis, Surgical | 2 | 2023 | 136 | 0.180 |
Why?
| | Gamma Rays | 1 | 2021 | 48 | 0.180 |
Why?
| | Interleukin-2 | 5 | 2022 | 413 | 0.180 |
Why?
| | Delivery of Health Care | 2 | 2021 | 833 | 0.180 |
Why?
| | Bacterial Translocation | 2 | 2019 | 36 | 0.180 |
Why?
| | Diarrhea | 3 | 2008 | 171 | 0.180 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 72 | 0.180 |
Why?
| | Group II Phospholipases A2 | 1 | 2020 | 19 | 0.170 |
Why?
| | Receptors, CCR | 1 | 2020 | 7 | 0.170 |
Why?
| | Carcinoembryonic Antigen | 2 | 2022 | 37 | 0.170 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2021 | 62 | 0.170 |
Why?
| | Cell Proliferation | 6 | 2021 | 2187 | 0.170 |
Why?
| | Interleukins | 2 | 2019 | 236 | 0.170 |
Why?
| | Risk Factors | 11 | 2019 | 8632 | 0.170 |
Why?
| | Platelet Count | 1 | 2020 | 81 | 0.170 |
Why?
| | Decision Making | 2 | 2019 | 782 | 0.170 |
Why?
| | Surgeons | 1 | 2023 | 239 | 0.170 |
Why?
| | Basophils | 1 | 2020 | 64 | 0.170 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 198 | 0.170 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 79 | 0.170 |
Why?
| | Patient Care Planning | 2 | 2016 | 139 | 0.170 |
Why?
| | Gastric Bypass | 1 | 2021 | 92 | 0.170 |
Why?
| | Apoptosis | 5 | 2021 | 2363 | 0.170 |
Why?
| | Scalp | 1 | 2019 | 29 | 0.170 |
Why?
| | Dacarbazine | 4 | 2012 | 99 | 0.170 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 167 | 0.160 |
Why?
| | Th17 Cells | 1 | 2019 | 58 | 0.160 |
Why?
| | Leukocyte Count | 1 | 2020 | 293 | 0.160 |
Why?
| | Sclerosing Solutions | 1 | 2019 | 9 | 0.160 |
Why?
| | Argon Plasma Coagulation | 1 | 2019 | 4 | 0.160 |
Why?
| | Immunophenotyping | 2 | 2017 | 274 | 0.160 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 2 | 2022 | 40 | 0.160 |
Why?
| | Germ-Free Life | 1 | 2019 | 28 | 0.160 |
Why?
| | Preoperative Care | 2 | 2018 | 319 | 0.160 |
Why?
| | Animals | 23 | 2022 | 31706 | 0.160 |
Why?
| | CD4 Antigens | 2 | 2011 | 123 | 0.160 |
Why?
| | Sclerotherapy | 1 | 2019 | 19 | 0.160 |
Why?
| | Haploinsufficiency | 1 | 2019 | 42 | 0.160 |
Why?
| | Immunotherapy | 4 | 2024 | 474 | 0.160 |
Why?
| | Survivors | 2 | 2015 | 411 | 0.160 |
Why?
| | Tissue and Organ Procurement | 1 | 2022 | 228 | 0.160 |
Why?
| | Nutritional Support | 1 | 2019 | 27 | 0.160 |
Why?
| | Self Expandable Metallic Stents | 1 | 2019 | 14 | 0.160 |
Why?
| | Abdominal Neoplasms | 2 | 2010 | 26 | 0.160 |
Why?
| | Mastocytosis | 1 | 2019 | 12 | 0.160 |
Why?
| | Photochemotherapy | 1 | 2019 | 29 | 0.160 |
Why?
| | Postoperative Period | 1 | 2020 | 289 | 0.160 |
Why?
| | Intestinal Perforation | 1 | 2019 | 39 | 0.160 |
Why?
| | CTLA-4 Antigen | 1 | 2019 | 76 | 0.160 |
Why?
| | Gram-Positive Bacteria | 1 | 2019 | 45 | 0.160 |
Why?
| | HLA-DR Antigens | 2 | 2011 | 219 | 0.160 |
Why?
| | Intestinal Obstruction | 1 | 2019 | 40 | 0.160 |
Why?
| | Gram-Negative Bacteria | 1 | 2019 | 66 | 0.160 |
Why?
| | Skin Pigmentation | 1 | 2019 | 39 | 0.160 |
Why?
| | Dilatation | 1 | 2019 | 60 | 0.160 |
Why?
| | Environmental Restoration and Remediation | 1 | 2018 | 7 | 0.160 |
Why?
| | Esophagus | 1 | 2020 | 225 | 0.160 |
Why?
| | Fibrosis | 1 | 2021 | 453 | 0.160 |
Why?
| | Hospitals | 2 | 2021 | 581 | 0.150 |
Why?
| | Brachytherapy | 1 | 2019 | 103 | 0.150 |
Why?
| | Germ-Line Mutation | 1 | 2019 | 130 | 0.150 |
Why?
| | Venous Thromboembolism | 2 | 2012 | 231 | 0.150 |
Why?
| | Liver | 4 | 2016 | 1637 | 0.150 |
Why?
| | Septins | 1 | 2018 | 40 | 0.150 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2018 | 22 | 0.150 |
Why?
| | Oncogene Proteins v-abl | 1 | 2017 | 4 | 0.150 |
Why?
| | Cell Movement | 4 | 2022 | 869 | 0.150 |
Why?
| | Laser Therapy | 1 | 2019 | 100 | 0.150 |
Why?
| | HIV | 1 | 2019 | 208 | 0.150 |
Why?
| | Enteral Nutrition | 2 | 2010 | 160 | 0.150 |
Why?
| | Down-Regulation | 1 | 2020 | 594 | 0.150 |
Why?
| | Dasatinib | 1 | 2017 | 46 | 0.140 |
Why?
| | Deglutition Disorders | 1 | 2019 | 118 | 0.140 |
Why?
| | Viral Tropism | 1 | 2017 | 24 | 0.140 |
Why?
| | Protein Kinase Inhibitors | 3 | 2018 | 785 | 0.140 |
Why?
| | Food, Formulated | 1 | 1997 | 14 | 0.140 |
Why?
| | Carcinoid Tumor | 1 | 2017 | 25 | 0.140 |
Why?
| | Neurofibromin 1 | 1 | 2017 | 22 | 0.140 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2017 | 24 | 0.140 |
Why?
| | Ampulla of Vater | 1 | 2017 | 30 | 0.140 |
Why?
| | Fatty Acids, Omega-3 | 1 | 1998 | 122 | 0.140 |
Why?
| | Disease Management | 1 | 2021 | 560 | 0.140 |
Why?
| | src-Family Kinases | 1 | 2017 | 88 | 0.140 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2019 | 203 | 0.140 |
Why?
| | Arginine | 1 | 1998 | 238 | 0.140 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 49 | 0.140 |
Why?
| | Gastric Emptying | 1 | 2017 | 40 | 0.140 |
Why?
| | Perioperative Care | 1 | 2018 | 127 | 0.140 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 750 | 0.140 |
Why?
| | Nutritional Status | 1 | 2019 | 287 | 0.140 |
Why?
| | Thrombelastography | 1 | 2018 | 180 | 0.140 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 179 | 0.140 |
Why?
| | Gastrectomy | 1 | 2017 | 82 | 0.140 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 192 | 0.140 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 39 | 0.140 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 29 | 0.140 |
Why?
| | Immunologic Memory | 2 | 2016 | 313 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2002 | 1214 | 0.130 |
Why?
| | Digestive System Neoplasms | 1 | 2016 | 8 | 0.130 |
Why?
| | Mortality | 1 | 2018 | 287 | 0.130 |
Why?
| | Genital Neoplasms, Female | 1 | 2017 | 70 | 0.130 |
Why?
| | Digestive System Surgical Procedures | 1 | 1997 | 91 | 0.130 |
Why?
| | Antigen Presentation | 1 | 2017 | 188 | 0.130 |
Why?
| | Genes, erbB-1 | 1 | 2016 | 17 | 0.130 |
Why?
| | Guidelines as Topic | 1 | 2018 | 243 | 0.130 |
Why?
| | Polysaccharides, Bacterial | 1 | 2016 | 66 | 0.130 |
Why?
| | Bystander Effect | 1 | 2016 | 15 | 0.130 |
Why?
| | Lymphocyte Depletion | 3 | 2013 | 116 | 0.130 |
Why?
| | Exons | 3 | 2019 | 302 | 0.130 |
Why?
| | United States | 11 | 2023 | 12183 | 0.130 |
Why?
| | Germinal Center | 1 | 2016 | 48 | 0.130 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 25 | 0.130 |
Why?
| | T-Lymphocyte Subsets | 2 | 2024 | 383 | 0.130 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 76 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 213 | 0.130 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2015 | 44 | 0.130 |
Why?
| | Morbidity | 3 | 2023 | 280 | 0.130 |
Why?
| | Postoperative Care | 1 | 1997 | 222 | 0.130 |
Why?
| | Adenoma | 1 | 2017 | 189 | 0.130 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 797 | 0.130 |
Why?
| | Cystadenoma, Mucinous | 1 | 2015 | 13 | 0.120 |
Why?
| | Cystadenocarcinoma, Mucinous | 1 | 2015 | 14 | 0.120 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2021 | 698 | 0.120 |
Why?
| | Quality of Life | 2 | 2019 | 2353 | 0.120 |
Why?
| | Phosphoproteins | 1 | 2017 | 298 | 0.120 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2015 | 68 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1140 | 0.120 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2016 | 211 | 0.120 |
Why?
| | Viral Load | 5 | 2018 | 405 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2021 | 1019 | 0.120 |
Why?
| | Ileus | 1 | 2014 | 10 | 0.120 |
Why?
| | Receptors, Ghrelin | 1 | 2014 | 7 | 0.120 |
Why?
| | Risk Assessment | 3 | 2019 | 2968 | 0.120 |
Why?
| | Ethanol | 1 | 2019 | 538 | 0.120 |
Why?
| | Dietary Supplements | 1 | 1998 | 460 | 0.120 |
Why?
| | Vinblastine | 2 | 2012 | 63 | 0.120 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2016 | 636 | 0.120 |
Why?
| | Endosonography | 1 | 2016 | 140 | 0.120 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2177 | 0.110 |
Why?
| | Tumor Cells, Cultured | 4 | 2021 | 849 | 0.110 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 60 | 0.110 |
Why?
| | Pilot Projects | 1 | 2018 | 1373 | 0.110 |
Why?
| | Fluorouracil | 2 | 2019 | 152 | 0.110 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 169 | 0.110 |
Why?
| | Tumor Burden | 4 | 2022 | 259 | 0.110 |
Why?
| | Blood Cell Count | 1 | 2013 | 50 | 0.110 |
Why?
| | RNA, Viral | 3 | 2013 | 565 | 0.110 |
Why?
| | Registries | 1 | 2021 | 1768 | 0.110 |
Why?
| | Colectomy | 3 | 2008 | 86 | 0.110 |
Why?
| | Databases, Factual | 4 | 2019 | 1125 | 0.110 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2013 | 81 | 0.110 |
Why?
| | Cisplatin | 2 | 2012 | 262 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2086 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 1 | 2016 | 447 | 0.110 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2013 | 59 | 0.110 |
Why?
| | Stomach | 2 | 2023 | 102 | 0.100 |
Why?
| | Oligopeptides | 1 | 2014 | 236 | 0.100 |
Why?
| | HIV Antibodies | 1 | 2013 | 49 | 0.100 |
Why?
| | Biomarkers | 2 | 2020 | 3408 | 0.100 |
Why?
| | Hospital Mortality | 2 | 2016 | 776 | 0.100 |
Why?
| | Side-Population Cells | 1 | 2012 | 9 | 0.100 |
Why?
| | Ablation Techniques | 1 | 2012 | 29 | 0.100 |
Why?
| | Chi-Square Distribution | 3 | 2014 | 493 | 0.100 |
Why?
| | Palatine Tonsil | 3 | 2017 | 32 | 0.100 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 126 | 0.100 |
Why?
| | Biological Therapy | 1 | 2012 | 26 | 0.100 |
Why?
| | Macrophages | 2 | 2001 | 1263 | 0.100 |
Why?
| | Efficiency, Organizational | 1 | 2013 | 125 | 0.100 |
Why?
| | Elective Surgical Procedures | 1 | 2013 | 151 | 0.100 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2012 | 102 | 0.100 |
Why?
| | Patient Care Team | 1 | 2016 | 517 | 0.100 |
Why?
| | Escherichia coli Infections | 1 | 2012 | 100 | 0.100 |
Why?
| | Time-to-Treatment | 1 | 2013 | 147 | 0.100 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2019 | 485 | 0.100 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2011 | 35 | 0.100 |
Why?
| | Predictive Value of Tests | 5 | 2018 | 1796 | 0.090 |
Why?
| | Proctocolectomy, Restorative | 1 | 2011 | 19 | 0.090 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 167 | 0.090 |
Why?
| | Colonic Pouches | 1 | 2011 | 14 | 0.090 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 4694 | 0.090 |
Why?
| | Intestinal Neoplasms | 1 | 2011 | 24 | 0.090 |
Why?
| | Ligands | 2 | 2023 | 562 | 0.090 |
Why?
| | Referral and Consultation | 1 | 2016 | 635 | 0.090 |
Why?
| | Antibodies, Neutralizing | 1 | 2013 | 222 | 0.090 |
Why?
| | Multivariate Analysis | 4 | 2016 | 1430 | 0.090 |
Why?
| | Extremities | 2 | 2022 | 113 | 0.090 |
Why?
| | Antigens, CD | 2 | 2015 | 442 | 0.090 |
Why?
| | Antigens, Neoplasm | 2 | 2009 | 222 | 0.090 |
Why?
| | Endocytosis | 1 | 2011 | 148 | 0.090 |
Why?
| | Cell Separation | 2 | 2010 | 291 | 0.090 |
Why?
| | Cohort Studies | 5 | 2019 | 4895 | 0.090 |
Why?
| | Heparin | 1 | 2012 | 224 | 0.090 |
Why?
| | Toll-Like Receptor 8 | 1 | 2010 | 5 | 0.090 |
Why?
| | Interleukin-23 | 1 | 2010 | 15 | 0.090 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2012 | 308 | 0.090 |
Why?
| | Vascular Surgical Procedures | 1 | 2013 | 259 | 0.090 |
Why?
| | Escherichia coli | 1 | 2014 | 720 | 0.090 |
Why?
| | Gastric Fistula | 1 | 2010 | 4 | 0.090 |
Why?
| | Toll-Like Receptor 7 | 1 | 2010 | 35 | 0.090 |
Why?
| | Double-Blind Method | 4 | 2014 | 1660 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2015 | 645 | 0.090 |
Why?
| | Cutaneous Fistula | 1 | 2010 | 13 | 0.090 |
Why?
| | Colitis, Ulcerative | 1 | 2011 | 105 | 0.090 |
Why?
| | Viremia | 1 | 2010 | 122 | 0.080 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1342 | 0.080 |
Why?
| | Caspase 3 | 1 | 2010 | 235 | 0.080 |
Why?
| | Phenotype | 5 | 2019 | 2796 | 0.080 |
Why?
| | Odds Ratio | 3 | 2019 | 953 | 0.080 |
Why?
| | Immunoglobulins | 2 | 2023 | 143 | 0.080 |
Why?
| | Cell Transplantation | 1 | 2009 | 36 | 0.080 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 961 | 0.080 |
Why?
| | Gastrostomy | 1 | 2010 | 91 | 0.080 |
Why?
| | Neoplastic Stem Cells | 1 | 2012 | 329 | 0.080 |
Why?
| | Paracrine Communication | 1 | 2009 | 56 | 0.080 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2024 | 615 | 0.080 |
Why?
| | Radiotherapy, Conformal | 1 | 2009 | 68 | 0.080 |
Why?
| | Age Factors | 3 | 2019 | 2894 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2022 | 1141 | 0.080 |
Why?
| | Prosthesis Implantation | 1 | 2010 | 138 | 0.080 |
Why?
| | Hyalin | 1 | 2008 | 5 | 0.080 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2008 | 25 | 0.080 |
Why?
| | Dermatofibrosarcoma | 1 | 2008 | 9 | 0.080 |
Why?
| | ras Proteins | 1 | 2009 | 138 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 811 | 0.080 |
Why?
| | Length of Stay | 3 | 2019 | 962 | 0.080 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2008 | 59 | 0.080 |
Why?
| | Chemokine CXCL12 | 1 | 2008 | 74 | 0.080 |
Why?
| | Interleukin-4 | 2 | 2007 | 206 | 0.080 |
Why?
| | DNA Mutational Analysis | 3 | 2016 | 372 | 0.070 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2008 | 130 | 0.070 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2023 | 194 | 0.070 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2024 | 439 | 0.070 |
Why?
| | Logistic Models | 4 | 2016 | 1841 | 0.070 |
Why?
| | Kidney Failure, Chronic | 1 | 2013 | 489 | 0.070 |
Why?
| | Critical Care | 1 | 2012 | 476 | 0.070 |
Why?
| | Anticoagulants | 1 | 2012 | 550 | 0.070 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2007 | 17 | 0.070 |
Why?
| | Deoxycytidine | 1 | 2008 | 138 | 0.070 |
Why?
| | Interleukin-6 | 4 | 1999 | 676 | 0.070 |
Why?
| | Phylogeny | 2 | 2024 | 789 | 0.070 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 66 | 0.070 |
Why?
| | Career Mobility | 1 | 2007 | 61 | 0.070 |
Why?
| | Mice, Knockout | 3 | 2022 | 2570 | 0.070 |
Why?
| | Interleukin-1beta | 2 | 2019 | 370 | 0.070 |
Why?
| | Watchful Waiting | 2 | 2018 | 55 | 0.070 |
Why?
| | alpha-Defensins | 1 | 2006 | 11 | 0.070 |
Why?
| | DNA, Bacterial | 2 | 2019 | 311 | 0.070 |
Why?
| | Computational Biology | 2 | 2024 | 530 | 0.070 |
Why?
| | Blood Transfusion | 1 | 2009 | 293 | 0.070 |
Why?
| | History, 20th Century | 1 | 2007 | 264 | 0.070 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 12 | 0.070 |
Why?
| | Immunohistochemistry | 5 | 2008 | 1629 | 0.070 |
Why?
| | Laparotomy | 1 | 2007 | 103 | 0.070 |
Why?
| | Collagen | 1 | 2008 | 415 | 0.060 |
Why?
| | Intestine, Small | 1 | 2007 | 122 | 0.060 |
Why?
| | Lipopolysaccharides | 1 | 2009 | 823 | 0.060 |
Why?
| | Interleukin-17 | 2 | 2019 | 104 | 0.060 |
Why?
| | Mice, Inbred BALB C | 5 | 2003 | 1144 | 0.060 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2005 | 41 | 0.060 |
Why?
| | Obesity, Morbid | 1 | 2008 | 197 | 0.060 |
Why?
| | Cell Line, Tumor | 3 | 2018 | 2710 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2007 | 248 | 0.060 |
Why?
| | Proto-Oncogene Proteins | 1 | 2009 | 608 | 0.060 |
Why?
| | Cell Division | 2 | 2005 | 758 | 0.060 |
Why?
| | Culture Media | 1 | 2005 | 155 | 0.060 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2016 | 52 | 0.060 |
Why?
| | Thoracic Neoplasms | 1 | 2005 | 32 | 0.060 |
Why?
| | Quality Improvement | 1 | 2012 | 950 | 0.060 |
Why?
| | Faculty, Medical | 1 | 2007 | 228 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2005 | 2553 | 0.060 |
Why?
| | Mice, Inbred Strains | 1 | 2005 | 396 | 0.060 |
Why?
| | Fellowships and Scholarships | 1 | 2007 | 227 | 0.060 |
Why?
| | Nitric Oxide | 2 | 2001 | 823 | 0.060 |
Why?
| | Leadership | 1 | 2007 | 292 | 0.060 |
Why?
| | Surgical Procedures, Operative | 1 | 2006 | 207 | 0.060 |
Why?
| | Carcinoma | 1 | 2006 | 198 | 0.060 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2004 | 50 | 0.060 |
Why?
| | Neoplasm Invasiveness | 2 | 2018 | 442 | 0.050 |
Why?
| | New York | 1 | 2023 | 106 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 23 | 0.050 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 29 | 0.050 |
Why?
| | Child | 4 | 2019 | 18415 | 0.050 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 12 | 0.050 |
Why?
| | Toll-Like Receptor 4 | 1 | 2005 | 287 | 0.050 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2023 | 40 | 0.050 |
Why?
| | Antigens, CD1 | 2 | 2015 | 57 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 92 | 0.050 |
Why?
| | Body Weight | 4 | 2003 | 869 | 0.050 |
Why?
| | Axilla | 2 | 2017 | 39 | 0.050 |
Why?
| | Hypoglycemia | 1 | 2007 | 387 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 296 | 0.050 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 8 | 0.050 |
Why?
| | Veterans | 1 | 2013 | 1249 | 0.050 |
Why?
| | Corticosterone | 1 | 2003 | 211 | 0.050 |
Why?
| | Dietary Proteins | 1 | 2003 | 122 | 0.050 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2022 | 56 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 309 | 0.050 |
Why?
| | Leptin | 1 | 2003 | 210 | 0.050 |
Why?
| | NF-kappa B | 1 | 2005 | 641 | 0.050 |
Why?
| | Precision Medicine | 2 | 2016 | 337 | 0.050 |
Why?
| | Propionates | 1 | 2021 | 34 | 0.050 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 238 | 0.050 |
Why?
| | Remission, Spontaneous | 1 | 2021 | 37 | 0.050 |
Why?
| | Mediastinoscopy | 1 | 2021 | 3 | 0.050 |
Why?
| | Body Mass Index | 1 | 2008 | 1959 | 0.050 |
Why?
| | Positron-Emission Tomography | 3 | 2008 | 259 | 0.050 |
Why?
| | Glycoproteins | 2 | 2015 | 304 | 0.050 |
Why?
| | Ephrin-B2 | 1 | 2021 | 36 | 0.050 |
Why?
| | Neoplasm Transplantation | 3 | 2012 | 228 | 0.050 |
Why?
| | Acetates | 1 | 2021 | 95 | 0.050 |
Why?
| | Cholangiography | 1 | 2000 | 17 | 0.050 |
Why?
| | Acetylation | 1 | 2021 | 211 | 0.050 |
Why?
| | Fibroblasts | 1 | 2005 | 838 | 0.050 |
Why?
| | Thoracoscopy | 1 | 2020 | 57 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2022 | 184 | 0.040 |
Why?
| | Tissue Banks | 1 | 2020 | 17 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 385 | 0.040 |
Why?
| | Esophageal Mucosa | 1 | 2020 | 17 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2021 | 106 | 0.040 |
Why?
| | Regression Analysis | 2 | 2019 | 945 | 0.040 |
Why?
| | Coloring Agents | 2 | 2012 | 72 | 0.040 |
Why?
| | Interleukin-12 Subunit p35 | 1 | 2019 | 3 | 0.040 |
Why?
| | Imaging, Three-Dimensional | 2 | 2016 | 512 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2019 | 31 | 0.040 |
Why?
| | Eating | 2 | 2003 | 344 | 0.040 |
Why?
| | Margins of Excision | 1 | 2019 | 29 | 0.040 |
Why?
| | Paclitaxel | 2 | 2012 | 190 | 0.040 |
Why?
| | Radiography | 2 | 2016 | 812 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2012 | 1226 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2017 | 3003 | 0.040 |
Why?
| | Tight Junctions | 1 | 2019 | 68 | 0.040 |
Why?
| | Organ Size | 2 | 2016 | 436 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2022 | 578 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 103 | 0.040 |
Why?
| | Montana | 1 | 2018 | 16 | 0.040 |
Why?
| | United States Environmental Protection Agency | 1 | 2018 | 23 | 0.040 |
Why?
| | Mitogens | 1 | 1998 | 58 | 0.040 |
Why?
| | Keratins | 2 | 2010 | 176 | 0.040 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 138 | 0.040 |
Why?
| | Cachexia | 1 | 1999 | 52 | 0.040 |
Why?
| | Interleukin-18 | 1 | 2019 | 219 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 445 | 0.040 |
Why?
| | Robotic Surgical Procedures | 1 | 2019 | 85 | 0.040 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 111 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2015 | 1693 | 0.040 |
Why?
| | Receptor, ErbB-2 | 1 | 2020 | 300 | 0.040 |
Why?
| | Pedigree | 1 | 2019 | 460 | 0.040 |
Why?
| | Qualitative Research | 1 | 2022 | 936 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2002 | 668 | 0.040 |
Why?
| | Perioperative Period | 1 | 2017 | 49 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2018 | 175 | 0.040 |
Why?
| | Jejunostomy | 1 | 1997 | 12 | 0.040 |
Why?
| | Femoral Fractures | 1 | 1998 | 66 | 0.040 |
Why?
| | Rosaniline Dyes | 2 | 2007 | 10 | 0.040 |
Why?
| | Dinoprostone | 1 | 1998 | 184 | 0.040 |
Why?
| | Operative Time | 1 | 2017 | 106 | 0.040 |
Why?
| | Candidiasis | 1 | 1997 | 51 | 0.040 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 103 | 0.030 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 150 | 0.030 |
Why?
| | Occipital Bone | 1 | 2017 | 17 | 0.030 |
Why?
| | Parotid Gland | 1 | 2017 | 24 | 0.030 |
Why?
| | Infection Control | 1 | 1998 | 135 | 0.030 |
Why?
| | Liver Circulation | 1 | 2016 | 19 | 0.030 |
Why?
| | DNA, Ribosomal | 1 | 2017 | 79 | 0.030 |
Why?
| | Quality of Health Care | 2 | 2012 | 573 | 0.030 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2016 | 33 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 554 | 0.030 |
Why?
| | Radiotherapy Dosage | 2 | 2008 | 244 | 0.030 |
Why?
| | Histones | 1 | 2021 | 535 | 0.030 |
Why?
| | Neck | 1 | 2017 | 85 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 367 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 1890 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 196 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 385 | 0.030 |
Why?
| | Models, Anatomic | 1 | 2016 | 87 | 0.030 |
Why?
| | Hydrogen Peroxide | 1 | 1998 | 288 | 0.030 |
Why?
| | Superinfection | 1 | 2016 | 5 | 0.030 |
Why?
| | Receptors, CXCR5 | 1 | 2016 | 11 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2008 | 182 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2017 | 4410 | 0.030 |
Why?
| | Feasibility Studies | 2 | 2010 | 740 | 0.030 |
Why?
| | Host Specificity | 1 | 2016 | 22 | 0.030 |
Why?
| | Incidental Findings | 1 | 2016 | 70 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 382 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 923 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2016 | 149 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1317 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2017 | 455 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 75 | 0.030 |
Why?
| | Prevotella | 1 | 2015 | 12 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2015 | 131 | 0.030 |
Why?
| | Virion | 1 | 2015 | 73 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 154 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 591 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2016 | 110 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2019 | 440 | 0.030 |
Why?
| | Cell Cycle | 1 | 2017 | 542 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2008 | 3053 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1998 | 395 | 0.030 |
Why?
| | CD40 Antigens | 1 | 2015 | 82 | 0.030 |
Why?
| | Glucocorticoids | 1 | 1999 | 532 | 0.030 |
Why?
| | Nausea | 1 | 2014 | 101 | 0.030 |
Why?
| | Patient Readmission | 1 | 2019 | 610 | 0.030 |
Why?
| | Mitotic Index | 1 | 2014 | 26 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 723 | 0.030 |
Why?
| | Cattle | 1 | 2016 | 920 | 0.030 |
Why?
| | Inflammation | 2 | 2019 | 2480 | 0.030 |
Why?
| | Colitis | 1 | 2016 | 223 | 0.030 |
Why?
| | Vomiting | 1 | 2014 | 123 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 442 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 268 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 2765 | 0.030 |
Why?
| | Phosphorylation | 1 | 1998 | 1569 | 0.030 |
Why?
| | Hemorrhage | 1 | 1998 | 620 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 1 | 2014 | 257 | 0.030 |
Why?
| | Caspase 1 | 1 | 2014 | 140 | 0.030 |
Why?
| | Cell Lineage | 1 | 2015 | 309 | 0.030 |
Why?
| | Autoantigens | 1 | 2016 | 396 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1395 | 0.030 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2013 | 10 | 0.030 |
Why?
| | Endarterectomy, Carotid | 1 | 2013 | 42 | 0.030 |
Why?
| | Clinical Competence | 1 | 2019 | 893 | 0.030 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2013 | 72 | 0.030 |
Why?
| | HIV Envelope Protein gp120 | 1 | 2013 | 56 | 0.030 |
Why?
| | AIDS Vaccines | 1 | 2013 | 41 | 0.030 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 33 | 0.030 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 29 | 0.030 |
Why?
| | International Agencies | 1 | 2012 | 30 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2013 | 176 | 0.030 |
Why?
| | Homeostasis | 1 | 2016 | 573 | 0.030 |
Why?
| | Adoptive Transfer | 1 | 2013 | 195 | 0.030 |
Why?
| | Thoracotomy | 1 | 2012 | 75 | 0.030 |
Why?
| | Response Elements | 1 | 2012 | 82 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2013 | 242 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2013 | 353 | 0.020 |
Why?
| | Calcium | 1 | 1998 | 1108 | 0.020 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2013 | 113 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 305 | 0.020 |
Why?
| | APACHE | 1 | 2012 | 58 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 171 | 0.020 |
Why?
| | Blood Coagulation Tests | 1 | 2012 | 57 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 314 | 0.020 |
Why?
| | Receptors, HIV | 1 | 2011 | 23 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 283 | 0.020 |
Why?
| | Transcriptome | 1 | 2017 | 725 | 0.020 |
Why?
| | Species Specificity | 1 | 2013 | 542 | 0.020 |
Why?
| | Bone Marrow | 1 | 2013 | 243 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 718 | 0.020 |
Why?
| | Cell Communication | 1 | 2013 | 280 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 237 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2012 | 258 | 0.020 |
Why?
| | Models, Animal | 1 | 2013 | 344 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1421 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1075 | 0.020 |
Why?
| | CA-19-9 Antigen | 1 | 2010 | 14 | 0.020 |
Why?
| | Factor Xa Inhibitors | 1 | 2012 | 138 | 0.020 |
Why?
| | Genes, bcl-2 | 1 | 2010 | 20 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 555 | 0.020 |
Why?
| | Risk | 1 | 2013 | 812 | 0.020 |
Why?
| | Cell Survival | 1 | 2014 | 1021 | 0.020 |
Why?
| | Universities | 1 | 2013 | 340 | 0.020 |
Why?
| | Mice, Nude | 1 | 2012 | 630 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1518 | 0.020 |
Why?
| | Incidence | 1 | 1996 | 2313 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 535 | 0.020 |
Why?
| | Patient Selection | 1 | 2014 | 641 | 0.020 |
Why?
| | Gastroscopy | 1 | 2010 | 18 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 134 | 0.020 |
Why?
| | Chronic Disease | 1 | 2015 | 1578 | 0.020 |
Why?
| | Renal Dialysis | 1 | 2013 | 374 | 0.020 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2009 | 65 | 0.020 |
Why?
| | Keratin-20 | 1 | 2008 | 1 | 0.020 |
Why?
| | N-Acetylgalactosaminyltransferases | 1 | 2008 | 6 | 0.020 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2008 | 11 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2013 | 770 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2013 | 1982 | 0.020 |
Why?
| | Chloroquine | 1 | 2009 | 52 | 0.020 |
Why?
| | Liver Regeneration | 1 | 2008 | 29 | 0.020 |
Why?
| | Device Removal | 1 | 2010 | 126 | 0.020 |
Why?
| | Prostheses and Implants | 1 | 2010 | 137 | 0.020 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2008 | 127 | 0.020 |
Why?
| | Chemokine CX3CL1 | 1 | 2008 | 21 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 159 | 0.020 |
Why?
| | Premedication | 1 | 2008 | 36 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 1715 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 45 | 0.020 |
Why?
| | Program Evaluation | 1 | 2012 | 822 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2008 | 67 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2008 | 89 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2785 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 228 | 0.020 |
Why?
| | Models, Molecular | 1 | 2013 | 1369 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 81 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 1949 | 0.020 |
Why?
| | Remission Induction | 1 | 2008 | 233 | 0.020 |
Why?
| | Acute Disease | 2 | 2003 | 911 | 0.020 |
Why?
| | Quinazolines | 1 | 2009 | 240 | 0.020 |
Why?
| | Swine | 1 | 2010 | 700 | 0.020 |
Why?
| | Body Composition | 2 | 2003 | 590 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 3535 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 510 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2007 | 195 | 0.020 |
Why?
| | Lewis X Antigen | 1 | 2006 | 4 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 225 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 993 | 0.020 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2007 | 170 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2320 | 0.020 |
Why?
| | Whole Body Imaging | 1 | 2006 | 19 | 0.020 |
Why?
| | Infant | 1 | 2019 | 7963 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2007 | 301 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2008 | 385 | 0.020 |
Why?
| | Patient Discharge | 1 | 2011 | 772 | 0.020 |
Why?
| | Radiotherapy | 1 | 2006 | 176 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2006 | 396 | 0.010 |
Why?
| | Base Sequence | 1 | 2008 | 2114 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 2004 | 79 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4099 | 0.010 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2003 | 59 | 0.010 |
Why?
| | Adrenalectomy | 1 | 2003 | 60 | 0.010 |
Why?
| | Appetite Regulation | 1 | 2003 | 26 | 0.010 |
Why?
| | Drug Implants | 1 | 2003 | 70 | 0.010 |
Why?
| | Random Allocation | 1 | 2003 | 335 | 0.010 |
Why?
| | Cycloheximide | 1 | 2001 | 54 | 0.010 |
Why?
| | Dactinomycin | 1 | 2001 | 25 | 0.010 |
Why?
| | Peritoneum | 1 | 2001 | 36 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2001 | 239 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2001 | 201 | 0.010 |
Why?
| | Mifepristone | 1 | 1999 | 60 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 1999 | 33 | 0.010 |
Why?
| | Mice, Inbred DBA | 1 | 1999 | 174 | 0.010 |
Why?
| | Candida albicans | 1 | 1997 | 50 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 1842 | 0.010 |
Why?
| | Obesity | 1 | 2008 | 2508 | 0.010 |
Why?
| | RNA | 1 | 2001 | 809 | 0.010 |
Why?
| | Injury Severity Score | 1 | 1996 | 499 | 0.010 |
Why?
| | Pregnancy | 1 | 2004 | 5518 | 0.010 |
Why?
| | Kidney | 1 | 1997 | 1188 | 0.010 |
Why?
|
|
McCarter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|